#hot_papers #Moscow #medicine

DNA Aptamers vs. Glioblastoma: A Precision Strike on Brain Cancer

Glioblastoma. The name alone is terrifying. It's the most aggressive brain tumor you can get—the one that resists treatment and almost always comes back.

The biggest hurdle? Delivery. The blood-brain barrier (BBB) protects the brain—but it also blocks chemotherapy. Getting drugs into the tumor without touching healthy tissue has been the holy grail.

Now, scientists from the Institute of Higher Nervous Activity and Neurophysiology RAS (Moscow) just published a study that brings us one step closer.

🎯 The weapon: DNA aptamers
Think of aptamers as synthetic antibodies—short DNA molecules designed to latch onto specific proteins with incredible precision. They're small, cheap to produce, and (unlike antibodies) don't trigger an immune reaction.

🔬 The breakthrough:
The team compared two aptamers targeting EGFRvIII—a mutant receptor overexpressed in glioblastoma cells.

Their improved version, Gol1, is shorter, more stable, and highly specific.
In rats with glioblastoma:
✅ FAM-labeled Gol1 accumulated exclusively in the tumor
✅ Maximum contrast in the invasive zone—the edge where cancer infiltrates healthy brain
✅ Zero signal in healthy tissue

But here's the kicker: Gol1 doesn't just find the tumor. It induces apoptosis—programmed cell death—in the cancer cells.

💊 Why it matters:
▫️ Non-immunogenic
▫️ Small size = better tissue penetration
▫️ Cheap to manufacture
▫️ Potential platform for theranostics (therapy + diagnostics)

This isn't a cure yet. It's a tool. But it's a sharp one.

🔗 Read the paper